A Comprehensive Multiomics Analysis Identified Ubiquilin 4 as a Promising Prognostic Biomarker of Immune-Related Therapy in Pan-Cancer

Figure 5

The CNV landscape of UBQLN4 in pan-cancer based on GSCA. (a) The deletion/amplification of heterozygous/homozygous CNV for UBQLN4 in various cancer types. (b) Correlation between CNV and UBQLN4 mRNA expression in various cancers. (c) Survival difference between CNV and wide type groups in pan-cancer. CNV: copy number variation; UBQLN4: ubiquilin 4; GSCA: Gene Set Cancer Analysis; Hete Amp: Heterozygous Amplification; Homo Amp: Homozygous Amplification; Hete Del: Heterozygous Deletion; Homo Del: Homozygous Deletion; OS: overall survival; PFS: progression-free survival; ACC: adrenocortical carcinoma; BLCA: bladder urothelial carcinoma; BRCA: breast invasive carcinoma; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL: cholangiocarcinoma; COAD: colon adenocarcinoma; DLBC: lymphoid neoplasm diffuse large B-cell lymphoma; ESCA: esophageal carcinoma; GBM: glioblastoma multiforme; HNSC: head and neck squamous cell carcinoma; KICH: kidney chromophobe; KIRC: kidney renal clear cell carcinoma; KIRP: kidney renal papillary cell carcinoma; LAML: acute myeloid leukemia; LGG: brain lower grade glioma; LIHC: liver hepatocellular carcinoma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; MESO: mesothelioma; OV: ovarian serous cystadenocarcinoma; PAAD: pancreatic adenocarcinoma; PCPG: pheochromocytoma and paraganglioma; PRAD: prostate adenocarcinoma; READ: rectum adenocarcinoma; SARC: sarcoma; SKCM: skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT: testicular germ cell tumor; THCA: thyroid carcinoma; THYM: thymoma; UCEC: uterine corpus endometrial carcinoma; UCS: uterine carcinosarcoma; UVM: uveal melanoma.

(a)

(b)

(c)